Here’s what you should know:
1. The event will be in New York City on April 27, from 8 a.m. to 10 a.m. EST, with a live stream available online under the investors section.
2. RedHill’s executive team and key opinion leaders will discuss Bekinda and applicable market aspects.
3. RedHill expects results from its phase III study on Bekinda in the second quarter of fiscal year 2017.
More articles on gastroenterology:
Bowel cancer mortality rates drop 30% — 4 study insights
GI leader to know: Dr. Louis Leite of Pennsylvania Gastroenterology
2 new GI-driven ASCs & facilities — March 2017
